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Abstract
The aim of this study was to determine whether vitamin D supplementation and maintaining vitamin D sufﬁciency are associated with changes
in inﬂammatory and metabolic biomarkers in patients with knee osteoarthritis (OA) and vitamin D deﬁciency. A total of 413 participants with
symptomatic knee OA and vitamin D deﬁciency were enrolled in a randomised, placebo-controlled trial and received 1·25mg vitamin D3 or
placebo monthly for 24 months across two sites. In this post hoc analysis, 200 participants from one site (ninety-four from the placebo group
and 106 from the vitamin D group; mean age 63·1 (SD 7·3) years, 53·3% women) were randomly selected for measurement of serum levels of
inﬂammatory and metabolic biomarkers at baseline and 24 months using immunoassays. In addition, participants were classiﬁed into two
groups according to serum 25-hydroxyvitamin D (25(OH)D) levels at months 3 and 24: (1) not consistently sufﬁcient (25(OH)D≤ 50 nmol/l at
either month 3 or 24, n 61), and (2) consistently sufﬁcient (25(OH)D> 50 nmol/l at both months 3 and 24, n 139). Compared with placebo,
vitamin D supplementation had no signiﬁcant effect on change in serum high-sensitive C-reactive protein, IL-6, IL-8, IL-10, leptin, adiponectin,
resistin, adipsin and apelin. Being consistently vitamin D sufﬁcient over 2 years was also not associated with changes in these biomarkers
compared with not being consistently sufﬁcient. Vitamin D supplementation and maintaining vitamin D sufﬁciency did not alter serum levels
of inﬂammatory and metabolic biomarkers over 2 years in knee OA patients who were vitamin D insufﬁcient, suggesting that they may not
affect systemic inﬂammation in knee OA patients.
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Osteoarthritis (OA) is a common chronic joint disease associated
with increased morbidity and disability risk and contributing to
an enormous ﬁnancial burden on healthcare systems world-
wide(1). In recent years, the pathophysiologic concept of OA has
been changed from a degenerative joint disorder to a more
complex concept involving multiple aetiologies and patho-
geneses(2). Inﬂammation is intricately linked to the aetiology of
OA and has been implicated in the pathogenesis of OA(3).
Experimental and observational studies have demonstrated that
inﬂammatory and/or metabolic biomarkers are mediators of the
inﬂammatory process of OA(4). In addition, there is increasing
evidence for a potential role of vitamin D deﬁciency in OA.
Vitamin D receptor (VDR) is expressed in chondrocytes, osteo-
clasts and osteoblasts(5), and vitamin D can reduce bone turnover
and cartilage degradation, and thus it has the potential to delay
the development and progression of OA(6).
Interestingly, several experimental studies have reported
that vitamin D may reduce the inﬂammatory response by
modulating human monocyte function or VDR signalling(7,8).
Observational studies have shown that vitamin D deﬁciency is
associated with increased inﬂammation in chronic conditions,
including asthma, inﬂammatory bowel disease and rheumatoid
arthritis (RA)(9,10). Such evidence suggests that increased
inﬂammation may be a key underlying mechanism linking
vitamin D deﬁciency to OA, and vitamin D could modify OA
disease progression through inhibition of inﬂammation.
Previous studies have examined the effect of vitamin D
supplementation on inﬂammatory biomarkers in older adults
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; hs-CRP, high-sensitivity C-reactive protein; OA, osteoarthritis.
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and patients with some chronic diseases, and have shown
inconsistent results(11–14), but no study has reported whether
vitamin D supplementation has effects on inﬂammatory and
metabolic biomarkers in OA patients.
Recently we reported that, compared with placebo, vitamin D
supplementation had no signiﬁcant effects on MRI-measured
tibial cartilage volume or the Western Ontario and McMaster
Universities Arthritis Index (WOMAC) assessed knee pain(15),
but signiﬁcantly reduced MRI-measured joint effusion–synovitis
in patients with symptomatic knee OA(16). This suggests that
vitamin D supplementation could have anti-inﬂammatory
effects by regulating serum levels of inﬂammatory or meta-
bolic biomarkers in knee OA patients. The aim of the
current study was, therefore, to determine whether vitamin D
supplementation affected serum inﬂammatory and metabolic
biomarkers and whether variation in vitamin D status over 2
years was associated with change in biomarkers in patients
with knee OA and vitamin D deﬁciency.
Methods
Study design and participants
This study was a post hoc analysis of the Vitamin D Effect on
Osteoarthritis (VIDEO) study, which was a multicentre rando-
mised, double-blind, placebo-controlled trial in knee OA
patients with vitamin D deﬁciency. The method and protocol of
the trial were described previously(17). The trial was conducted
from June 2010 to December 2013.
In brief, eligible participants who had knee symptomatic OA
(assessed using American College of Rheumatology criteria)(18) at
least for 6 months and had pain of >20mm on a 100-mm visual
analogue scale (VAS) with low levels of 25-hydroxyvitamin D
(25(OH) D, between 12·5 and 60nmol/l) were enrolled in
Tasmania and Victoria, Australia. Participants with the following
conditions were excluded: severe radiographic changes (grade 3
of Altman and Gold Atlas)(19), severe knee pain on standing
(>80mm on a 100-mm VAS), contraindications to MRI, RA or
psoriatic arthritis, lupus, cancer, severe cardiac or renal impair-
ment, hypersensitivity to vitamin D, conditions affecting oral drug
absorption, anticipated knee or hip surgery within the next
2 years, history of signiﬁcant trauma of knees (e.g. arthroscopy or
injury to ligaments or menisci within 1 year preceding the study)
and history of taking vitamin D or other investigational drugs,
such as some compound drugs including vitamin D that affected
serum vitamin D levels, within the last 30 d(17).
After the trial had been completed, 200 participants were
randomly selected for the measurements of inﬂammatory and
metabolic biomarkers from Tasmania.
Ethics approval was received from Tasmania Health and
Human Medical Research Ethics Committee (reference number
H1040) and Monash University Human Research Ethics Com-
mittee (reference no. CF10/1182-2010000616).
Randomisation and treatment
Participants were allocated to either vitamin D or placebo arm
at a ratio of 1:1 based on computer-generated random numbers.
Allocation concealment was ensured by a centrally automated
allocation procedure with security in place to ensure
that allocation data cannot be accessed or inﬂuenced by any
person from the investigative team. Participants received
oral vitamin D capsules at a dose of 1·25mg vitamin D3 (cho-
lecalciferol) per month for 24 months in the treatment group.
Participants received an identical inert placebo capsule in the
placebo group(17).
Serum inﬂammatory and metabolic biomarker level
measurement
All fasting blood samples were collected at baseline and at
24 months. The measurements were performed according to
the manufacturer’s instruction. Serum levels of high-sensitive
C-reactive protein (hs-CRP), IL-6, IL-8, IL-10, resistin, leptin,
adiponectin, adipsin and apelin-36 were measured. Serum
hs-CRP was measured by enzyme immunoassays (IBL Inc.).
Serum leptin and apelin-36 were measured by ELISA (Phoenix
Pharmaceuticals Inc.). Serum adiponectin, adipsin and resistin
were measured by ELISA (Millipore Inc.). Serum IL-6, IL-8 and
IL-10 were measured by Bio-plex Luminex assay kits (Bio-Rad
Laboratories Inc.). The inter-assay and intra-assay CV were
<10 and <15% for all inﬂammatory biomarkers.
Serum vitamin D level measurement
Serum 25-hydroxyvitamin D (25(OH)D) was measured at
baseline, and at months 3 and 24 using direct competitive
chemiluminescent immunoassays (DiaSorin Inc.). The intra-
assay and inter-assay CV were 3·2 and 6·0%, respectively(15). In
addition, the season of blood sample was recorded. In this
study, we deﬁned serum 25-(OH)D below than 50 nmol/l as
vitamin D deﬁciency.
Variation in vitamin D status
Participants were classiﬁed into two groups according to the
levels of 25(OH)D at months 3 and 24 as follows: not con-
sistently sufﬁcient (serum 25(OH)D≤ 50 nmol/l at either month
3 or 24), and consistently sufﬁcient (serum 25(OH)D> 50nmol/l
at both months 3 and 24).
Assessment of effusion–synovitis and cartilage volume
MRI scans of the study knee were obtained according to
a standardised protocol using a 1·5 T whole-body MRI unit with
a commercial transmit-receive extremity coil at baseline and
2 years.
Effusion–synovitis was assessed using T2-weighted fast-spin
echo sequences at four regions (suprapatellar pouch, central
portion, posterior femoral recess and subpoploteal recess).
Effusion–synovitis in each subregion was scored individually
according to Whole-Organ Magnetic Resonance Imaging Score,
grading collectively from 0 to 3 in terms of the estimated
maximal distention of the synovial cavity: 0 refers to normal;
1 to <33% of maximum potential distention; 2 to 33–66% of
maximum potential distention; and 3 to >66% of maximum
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potential distention. The presence of effusion–synovitis of the
whole joint was deﬁned as a score of ≥2 in any subregion(16).
Effusion–synovitis volumes at 4 regions were isolated from
the total volume selecting each region of interest according to
the intra-articular ﬂuid-equivalent signal on a section-by-section
basis and then resampled by means of bilinear and cubic
interpolation for ﬁnal 3D rendering using OsiriX imaging
software (32-bit version 5.9; Pixmeo SARL). The intra-class
correlation coefﬁcients were from 0·96 to 0·97(20).
Cartilage volume was determined using the previously
described image processing techniques(17). The volumes of
individual cartilage plates (medial tibial and lateral tibial) were
isolated by manually drawing disarticulation contours around
the cartilage boundaries on a section-by-section basis and then
resampled using bilinear and cubic interpolation for ﬁnal three-
dimensional rendering using OsiriX imaging software. The CV
was 2·1 to 2·2%(20). Total tibial cartilage volume was calculated
as the sum of the medial tibia and lateral tibial cartilage plates.
Change in cartilage volume and effusion–synovitis volume
was calculated as follows: Absolute change (ml)= (follow-up
volume) − (baseline volume).
Anthropometrics
Height was measured to the nearest 0·1 cm (with shoes
removed) using a stadiometer (Leicester Height Measure;
Invicta Plastics Ltd). Weight was measured to the nearest 0·1 kg
(with shoes and bulky clothing removed) using electronic
scales (Heine S-7307; Heine). BMI (kg/m2) was calculated.
Data analyses
Very few studies have examined the effect of vitamin D
supplementation on inﬂammatory biomarkers; therefore, there
was limited information to inform our sample size calculation.
On the basis of a systematic review, the absolute difference in
serum hs-CRP between people with OA and healthy controls is
estimated as 1·19mg/l(21). Data from the Tasmanian Older Adult
Cohort Study provided a SD estimate of 2·78mg/l. With these
estimates, a sample size of eighty-seven in each group would
give 80% power with a 5% probability of type 1 error (α= 0·05,
β= 0·8)(22) to detect this effect size for hs-CRP.
Baseline characteristic differences between the vitamin D
supplementation and placebo groups were compared using
Student’s t tests or χ2 tests as appropriate. Box–Cox transfor-
mation was used, when variables were not normally distributed,
and transformed variables were used in the following analyses.
The differences in changes of inﬂammatory biomarkers
between treatment and placebo groups were analysed using
linear mixed effects model with adjustment for age, sex, BMI
and seasonal change of blood sampling. The within-subject
correlation between the repeated measures, including baseline
and follow-up data, was taken into account using the individual
participant identiﬁcation as a random effect. The effect of
vitamin D supplementation on biomarkers was evaluated by the
interaction between treatment and time (i.e. month). The
differences in changes of inﬂammatory biomarkers between not
consistently sufﬁcient and consistently sufﬁcient groups were
analysed using linear mixed effects model with adjustment
for age, sex, BMI and seasonal change of blood sampling.
Subgroup analyses were performed in participants with or
without effusion–synovitis at baseline. We also have taken the
weight change as confounder into analyses to make sure that
the weight change did not play a role in this study. Further
adjustment for changes in cartilage volume and effusion–
synovitis volume was performed to account for the effect of
disease progression on serum biomarker change. We used Stata
12.0 for Windows (StataCorp LP) for all analyses. A P value
<0·05 (two-tailed) was regarded as statistically signiﬁcant.
Results
Baseline characteristics of participants
A total of 599 participants were screened for eligibility, 413
participants were enrolled and randomly assigned to vitamin D
or placebo group (261 participants in Hobart and 152 partici-
pants in Melbourne) and 340 participants (82·0% retention rate
in Hobart and 83·6% retention rate in Melbourne) completed
the study (Fig. 1). A total of 200 participants from Hobart were
randomly selected for the inﬂammatory biomarker measure-
ments: ninety-four participants from the placebo group and 106
from the vitamin D treatment group. The mean age of partici-
pants was 63·1 years: 107 (53·5%) were women and mean BMI
was 29·5 kg/m2. There were no signiﬁcant differences in base-
line characteristics (age, sex, BMI, serum 25(OH)D level, serum
inﬂammatory biomarkers levels and season of blood sample)
between the placebo and vitamin D groups (Table 1). There
were no signiﬁcant differences in baseline characteristics
between those included and not included in this study (data not
shown). Signiﬁcant differences in baseline characteristics,
inﬂammatory and metabolic biomarkers between consistently
sufﬁcient and not consistently sufﬁcient groups were not found
(data not shown).
Vitamin D supplementation and inﬂammatory and
metabolic biomarkers
The mean serum 25(OH)D level increased signiﬁcantly in the
vitamin D treatment group (44·9 nmol/l) compared with the
placebo group (7·0 nmol/l) over 2 years. The effect of vitamin D
treatment on cytokines and adipokines is shown in Table 2.
Vitamin D supplementation had no signiﬁcant effect on change
in serum inﬂammatory and metabolic biomarkers. There were
no statistically signiﬁcant differences in changes in any bio-
markers between the placebo and vitamin D groups. After
further adjustment for potential confounders including the
seasonal change of blood sample, the differences between
groups remained non-signiﬁcant in the mixed effect model
(Table 2). Within the group, serum resistin increased by
1·9 pg/ml (95% CI 0·1, 3·8) in the placebo group and by
4·4 pg/ml (95% CI 2·7, 6·2) in the vitamin D group from base-
line to month 24. Difference in change in serum resistin
between two groups was of borderline statistical signiﬁcance
(P= 0·05). Serum adipsin increased by 0·2 ng/ml (95% CI
0·1, 0·4) in the vitamin D group, but did not increase in the
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placebo group from baseline to month 24. Serum hs-CRP, IL-6,
IL-8, IL-10, leptin, adiponectin and apelin did not change
signiﬁcantly over 24 months in either group.
Further analyses were performed in participants who had
baseline effusion–synovitis or not. Results remained largely
unchanged (data not shown). The results remained unchanged
after further adjustment for change in weight, and changes in
cartilage volume and effusion–synovitis volume (data not shown).
Vitamin D status and change in biomarkers
There were no statistically signiﬁcant differences in changes
of these biomarkers between consistently sufﬁcient and not
consistently sufﬁcient groups (Table 3). In the consistently
vitamin D sufﬁcient group, there were signiﬁcant increases in
serum resistin and adipsin (3·8 pg/ml and 0·3 ng/ml, respec-
tively) and a signiﬁcant decrease in serum IL-8 (3·0 pg/ml) from
baseline to month 24 (Table 3). In contrast, there was no sig-
niﬁcant change over the study period in the not consistently
sufﬁcient group. Serum IL-6, IL-10, CRP, leptin, adiponectin and
apelin did not change signiﬁcantly from baseline to month 24 in
either group.
The results remained largely unchanged if patients with and
without baseline effusion–synovitis were separated for analyses
(data not shown). Results remained largely unchanged after
further adjustment for changes in weight, cartilage volume and
effusion–synovitis volume (data not shown). In addition, no
signiﬁcant associations were found between the changes in
inﬂammatory/metabolic biomarkers and change in 25(OH)D
over 24 months, and the results remained largely unchanged
after further adjustment for the baseline serum 25(OH)D level
(except for change in resistin, P= 0·04) (data not shown).
Discussion
To the best of our knowledge, this study is the ﬁrst to explore
the effect of vitamin D supplementation on inﬂammatory and
metabolic biomarkers in patients with knee OA and to compare
the effect of vitamin D sufﬁciency on levels of serum inﬂam-
matory and metabolic biomarkers in OA patients. Vitamin D
supplementation had no signiﬁcant effects on serum inﬂam-
matory and metabolic biomarkers in patients with knee OA.
Furthermore, there were no signiﬁcant differences in serum
inﬂammatory and metabolic biomarkers between those who
were consistently sufﬁcient and those who were not over
24 months. These results suggest that vitamin D supplementa-
tion and maintaining sufﬁcient vitamin D status may not have
effects on systemic inﬂammation in knee OA patients.
Low-grade systemic inﬂammation triggered by abnormally
inﬂammatory or metabolic biomarkers has been implicated in
the OA pathogenesis. There is a vast amount of evidence
linking inﬂammatory biomarkers and OA, as well as the
Hobart
422 Participants screened
for eligibility
Melbourne
152 Randomised 261 Randomised
129 Randomised to
receive vitamin D
106 Inflammatory
biomarkers
measurements
94 Inflammatory
biomarkers
measurements
132 Randomised to
receive placebo
186 Excluded
42 Taking vitamin D
33 Exclusionary co-morbidities
26 Surgery scheduled
26 Withdrew consent
22 Severe radiographic osteoarthritis
15 Ineligible visual analogue scale
pain score
12 Physically unwell
4 Ineligible vitamin D
4 Contraindication to MRI
2 Ineligible age
73 Lost to follow-up
29 Discontinued regimen
12 Surgery
10 Relocated
4 Physically unwell
1 Died
17 Others
80 Randomised to
receive vitamin D
69 Completed 58 Completed 112 Completed 102 Completed
73 Randomised to
receive placebo
177 Participants screened
for eligibility
Fig. 1. Flowchart of the study.
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association between vitamin D and inﬂammation. Serum
hs-CRP levels were statistically signiﬁcantly higher in the OA
group than in the control group and were associated with
increased pain and decreased physical function(21). Serum IL-6
was correlated with radiographic OA, knee cartilage loss and
increased knee pain over time(23,24). Adipokines such as leptin
and resistin may disrupt cartilage homoeostasis by directly
inducing joint structural degradation or regulating local
inﬂammatory processes and are regarded as metabolic bio-
markers in the inﬂammatory process of OA(25,26). Serum leptin
was associated with reduced knee cartilage volume and
increased loss of cartilage thickness(27). Furthermore, high
serum leptin and IL-6 were associated with reduced 25(OH)D
levels over time(28). These suggest that systemic inﬂammation
triggered by inﬂammatory or metabolic biomarkers may be a
key underlying mechanism linking vitamin D deﬁciency to OA.
Although there has been no previous RCT examining the
effect of vitamin D supplementation on inﬂammatory and
metabolic biomarkers in knee OA patients, some RCT have
examined the effect in healthy individuals, older adults or
patients with other chronic diseases such as obesity, asthma,
diabetes and chronic kidney disease, and reported inconsistent
results(29). The inconsistency between these study ﬁndings may
be caused by small sample sizes, diverse characteristics of
participants, treatment with different doses and measurements
of different inﬂammatory and metabolic biomarkers for the
different clinical trials(30). For example, two RCT with small
sample size were conducted in patients with diabetes. One
study reported that supplementation with 1·25mg vitamin D per
2 weeks for 12 weeks in 60 patients signiﬁcantly reduced serum
hs-CRP level compared with the placebo group(31), but another
study reported that treatment with 1·25mg/week vitamin D
and/or 1000mg Ca/d twice for 8 weeks did not result in sig-
niﬁcant difference in change in serum CRP and leptin, but did
result in signiﬁcant reduction in serum IL-6 and TNF-α com-
pared with the placebo group in 118 diabetic patients(12).
Our results are consistent with ﬁndings from RCT in healthy
or older adults without speciﬁc health conditions as vitamin D
supplementation in these groups has shown no effect on
inﬂammatory and metabolic biomarkers(32–35). A randomised
placebo-controlled trial was conducted in elderly adults without
a speciﬁc disease in Australia, aiming to examine the effects of
vitamin D supplementation for 12 months on hs-CRP, leptin,
adiponectin, IL-6 and IL-10(36). IL-6 was numerically higher in
those participants supplemented with 1500 µg/month vitamin D
compared with those supplemented with 750 µg/month,
Table 1. Baseline characteristics of participants
(Mean values and standard deviations; numbers and percentages;
medians and interquartile ranges (IQR))
Vitamin D group
(n 106)
Placebo group
(n 94)
Mean SD Mean SD P *
Age (years) 63·3 7·5 62·8 7·3 0·60
Women 0·29
n 53 54
% 50·0 57·4
BMI (kg/m2)† 29·4 7·5 29·6 4·0 0·80
Serum 25(OH)D (nmol/l) 42·5 11·7 43·5 12·6 0·57
Serum biomarker
hs-CRP (µg/ml)‡ 0·62
Median 1·5 1·3
IQR 0·8, 2·6 0·7, 2·5
IL-6 (pg/ml)‡ 0·81
Median 1·4 1·2
IQR 0·4, 3·8 0·4, 3·7
IL-8 (pg/ml)‡ 0·98
Median 7·8 7·6
IQR 5·7, 10·4 6·1, 10·9
IL-10 (pg/ml)‡ 0·56
Median 0·9 0·6
IQR 0·3, 5·2 0·3, 3·5
Resistin (pg/ml) 38·4 14·9 39·3 13·2 0·32
Leptin (ng/ml)‡ 0·90
Median 19·2 23·6
IQR 9·4, 58·1 9·7, 44·1
Adiponectin (ng/ml)‡ 0·11
Median 32·9 26·5
IQR 18·2, 50·3 15·5, 43·8
Adipsin (ng/ml) 4·0 1·5 3·9 1·2 0·84
Apelin (ng/ml) 1·0 0·3 1·0 0·4 0·84
25(OH)D, 25-hydroxyvitamin D; hs-CRP, high-sensitivity C-reactive protein.
* Student’s t tests or χ2 tests.
† BMI was calculated as weight in kg divided by height in m2.
‡ Skewed distribution.
Table 2. Comparisons of change in inflammatory biomarkers between vitamin D and placebo groups over 24 months
(Mean values and 95% confidence intervals)
Vitamin D group (change, n 106) Placebo group (change, n 94) Between-group (difference)
Mean* 95% CI Mean* 95% CI Mean† 95% CI P
Serum 25(OH)D (nmol/l) 45·0 40·8, 49·0 7·4 3·0, 11·8 37·5 31·5, 43·6 0·00
hs-CRP (µg/ml) 0·3 −0·2, 0·7 − 0·0 −0·5, 0·5 0·3 −0·4, 1·0 0·43
IL-6 (pg/ml) −2·3 −5·6, 0·9 −0·7 −4·2, 2·8 −1·6 −6·4, 3·2 0·51
IL-8 (pg/ml) −3·1 −6·5, 0·3 −0·0 −3·7, 3·6 −3·1 −8·1, 2·0 0·24
IL-10 (pg/ml) −2·0 −9·3, 5·3 −0·7 −8·5, 7·1 −1·3 −12·0, 9·4 0·81
Resistin (pg/ml) 4·4 2·7, 6·2 1·9 0·1, 3·8 2·5 −0·0, 5·1 0·05
Leptin (ng/ml) −0·2 −3·4, 3·0 −0·8 −4·2, 2·6 0·6 −4·0, 5·3 0·79
Adiponectin (ng/ml)‡ 0·01 −0·02, 0·04 0·00 −0·03, 0·03 0·01 −0·04, 0·06 0·66
Adipsin (ng/ml) 0·2 0·1, 0·4 0·1 −0·0, 0·3 0·1 −0·1, 0·3 0·39
Apelin (ng/ml) −0·1 −0·1, 0·0 0·0 −0·1, 0·1 −0·1 −0·2, 0·0 0·13
25(OH)D, 25-hydroxyvitamin D; hs-CRP, high-sensitivity C-reactive protein.
* Changes in inflammatory biomarkers are generated from mixed models adjusted for age, sex, BMI and change in season of blood sampling.
† Between-group difference was calculated using vitamin D group values minus placebo group values.
‡ Box–Cox transformation.
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although this was not signiﬁcant. In our current study, we found
that vitamin D supplementation had no signiﬁcant effect on
serum inﬂammatory and metabolic biomarkers, with the
exception of a possible effect on serum resistin, in patients with
knee OA. Serum resistin increased twofold in the vitamin D
group than in the placebo group, but the difference was of
borderline signiﬁcance. Although evidence shows that serum
resistin is a pro-inﬂammatory cytokine and is positively asso-
ciated with severity of OA(37), the clinical relevance of this
ﬁnding is unknown. Subgroup analyses were performed in
participants who had baseline effusion–synovitis or not, and
results remained unchanged. We previously reported that
vitamin D supplementation relieved the progression of
effusion–synovitis in patients with an inﬂammatory OA
phenotype(16). These indicated that vitamin D supplementation
would have effects on local rather than systemic inﬂammation.
The underlying mechanisms are unclear and need to be
explored by further studies.
A high proportion of participants in the placebo group
achieved sufﬁcient vitamin D level in month 24 (62% partici-
pants >50 nmol/l) in the VIDEO study, which may have masked
the effect of vitamin D supplementation on inﬂammatory
and metabolic biomarkers. Therefore, we performed further
post hoc analyses to examine whether maintaining sufﬁcient
vitamin D level over the treatment period had effects on the
biomarkers. Although serum resistin and adipsin increased,
and serum IL-8 decreased from baseline to month 24 in the
consistently vitamin D sufﬁcient group, changes in serum
resistin, adipsin and IL-8 were not signiﬁcantly different
between the patients with different vitamin D status. Until now,
only one cross-sectional study compared the level of inﬂam-
matory cytokines (IL-1β, 2, 4, 5, 6, 8, 10, 12, 13 and hs-CRP) in
different serum vitamin D status (deﬁcient, insufﬁcient or suf-
ﬁcient) in patients with knee OA(38), and did not ﬁnd that
vitamin D status was associated with circulating inﬂammatory
biomarkers. These results were generally consistent with the
ﬁndings in our current study. Maintaining serum vitamin D
sufﬁciency may not have effects on systemic inﬂammation in
knee OA patients.
We used the direct competitive chemiluminescent immuno-
assays (Diasorin Liaison assay) to measure the serum
25(OH)D, which may not be as sensitive and speciﬁc as HPLC
methodology; however, it showed good correlation with
HPLC, and would also be speciﬁc for both 25(OH)D2 and
25(OH)D3
( 39,40). The vitamin D status, measured via serum
25(OH)D concentrations, can be affected by factors such as
obesity. In addition, expression of vitamin D-dependent genes
could be served as a marker of vitamin D status, and this may
also inﬂuence the effect of vitamin D supplementation on
inﬂammatory markers(41,42). These need to be explored in
future studies.
There were some limitations of the current study. First, it was
a post hoc analysis within a subsample of an RCT, which was
not designed to examine the effect of vitamin D supplementa-
tion on inﬂammatory and metabolic biomarkers in patients with
knee OA. The ﬁndings need to be conﬁrmed by further RCT
using these biomarkers as the primary end points. Second, this
study had reduced sample size than what was designed for the
original study. However, the sample size is sufﬁcient to detect a
signiﬁcant difference for hs-CRP. Third, there was a high pro-
portion of participants in the placebo group who achieved
sufﬁcient vitamin D levels at months 3 and 24 (62% participants
>50 nmol/l) in the RCT study, which could have diluted the
effect of vitamin D supplementation. Thus, we performed
further post hoc analyses using variations in vitamin D status
over the treatment period and the results were consistent.
Fourth, three time points (baseline, 3 months and 24 months)
may not be adequate to deﬁne the ‘consistently or incon-
sistently vitamin D sufﬁcient’, and the inﬂammatory and
metabolic markers were not measured at an intermediate time
point. It was unknown whether vitamin D supplementation
had intermediate effects on inﬂammatory markers in knee OA
patients. Therefore, further studies are required.
Conclusion
Vitamin D supplementation and maintaining vitamin D sufﬁ-
ciency did not alter serum levels of inﬂammatory and metabolic
Table 3. Comparison of change in inflammatory biomarkers between different vitamin D status over 24 months
(Mean values and 95% confidence intervals)
Consistently sufficient (change, n 139) Not consistently sufficient (change, n 61) Between-group (difference)
Mean* 95% CI Mean* 95% CI Mean 95% CI† P
Serum 25(OH)D (nmol/l) 37·8 34·1, 41·6 3·1 −2·6, 8·7 34·8 28·0, 41·6 0·00
hs-CRP (µg/ml) 0·2 −0·2, 0·7 −0·1 −0·7, 0·6 0·3 −0·5, 1·1 0·46
IL-6 (pg/ml) −2·8 −5·7, 0·0 1·3 −3·0, 5·6 −4·1 −9·3, 1·0 0·12
IL-8 (pg/ml) −3·0 −6·0, −0·0 1·4 −3·1, 6·0 −4·5 −9·9, 1·0 0·11
IL-10 (pg/ml) −3·3 −9·6, 3·1 2·9 −6·8, 12·6 −6·2 17·8, 5·4 0·29
Resistin (pg/ml) 3·8 2·3, 5·4 1·9 −0·4, 4·3 1·9 −0·9, 4·7 0·18
Leptin (ng/ml) −0·1 −2·9, 2·7 −1·3 −5·5, 2·9 1·1 −3·9, 6·2 0·66
Adiponectin (ng/ml)‡ 0·02 −0·01, 0·04 −0·01 −0·06, 0·03 0·03 −0·02, 0·08 0·26
Adipsin (ng/ml) 0·3 0·1, 0·4 0·1 −0·1, 0·3 0·2 −0·1, 0·4 0·13
Apelin (ng/ml) −0·0 −0·1, 0·0 −0·1 −0·1, 0·0 0·0 −0·1, 0·1 0·72
25(OH)D, 25-hydroxyvitamin D; hs-CRP, high-sensitivity C-reactive protein.
* Changes in inflammatory biomarkers are generated from mixed models adjusted for vitamin D treatment, age, sex, BMI and change in season of blood sampling.
† Between-group difference was calculated using consistently sufficient group values minus not consistently sufficient group values.
‡ Box–Cox transformation.
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biomarkers over 2 years in knee OA patients who were
vitamin D insufﬁcient, suggesting that they may not affect sys-
temic inﬂammation in knee OA patients.
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